The
global market for human reproductive technologies was valued at USD
23.0 billion in 2012 and is expected to reach USD 27.1 billion in
2019, growing at a CAGR of 2.2% from 2013 to 2019.
Human
reproductive technologies include procedures and therapies for
conceiving or controlling pregnancy by means of artificial and/or
semi artificial medical solutions. Lack of awareness about the
reproductive deficiencies and their treatment necessity and
availability has been limiting the market to explore its potential
value. Therefore, awareness strategies adopted by market players with
proper guidance for patients will fuel the emerging human
reproductive technologies market especially the infertility treatment
market. Developing regions such as the Asia-Pacific, Latin America,
Africa and Middle-East hold the maximum growth potential in the human
reproductive technologies market. Some of the other factors
contributing to the growth of human reproductive technologies market
include delay in conceiving, lifestyle habits such as smoking,
excessive alcohol consumption, increasing use of contraceptive pills
and devices, and rising incidences of infertility.
Browse
Global Human Reproductive Technologies Market Report with Full TOC at
http://www.transparencymarketresearch.com/human-reproductive-technologies-market.html
The
infertility treatment market is characterized by the presence of many
leading patented drug brands which are restraining the entry of
generics and hence, creating a monopolistic situation. In addition,
due to patient sentiments attached to infertility treatment
procedures, risk ofno conception due to a low-quality generic drugis
usually avoided. This report includes market analysis for seven major
(by sales) branded formulations of infertility drugs, namely,
Gonal-f, Follistim AQ, AndroGel, Testim, Viagra, Cialis and
Levitra/Staxyn. Similarly, the contraceptive drugs and devices market
has many drugs in the research pipeline awaiting commercialization to
grab a share of this potential market. Large and well established
pharmaceutical players such as Merck Serono, Merck & Co., Inc.,
Bayer AG, Pfizer, Inc., Actavis plc, Ferring International Center
S.A. and Teva Pharmaceutical Industries Ltd. dominate the human
reproductive technologies market.
The
global contraceptives market was valued at USD 16.0billion in 2012
and is expected to grow at a CAGR of 5.5% from 2013 to 2019. The oral
contraceptive pills market lead the overall contraceptives market in
2012 in terms of revenue, mainly due to increasing population
awareness through advertisements enabling patients to buy them
over-the-counter. In the contraceptive devices market, male condoms
formed the largest market segment owing to the increased
accessibility and awareness along with their ease of use.
Request
for customization of this report
http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1876
The
infertility drugs market studied in this report include leading
brands from three drug classes, namely, gonadotropins, androgens and
erectile dysfunction drugs. Among these, Viagra was the largest brand
by revenue in 2012 among others considered in the study due to
increasing cases of erectile dysfunction in male infertility.
Moreover, it has been a well-established and popular brand since its
approval in 1998 by the U.S. FDA. Gonal-f in the gonadotropin class
is the leading brand prescribed by majority of the infertility
specialist due to better results achieved using it. For testosterone
deficiency which is one of the major infertility causes in male
patients, AndroGel is the blockbuster drug being preferred for the
treatment. Generic manufacturers such as Watson Pharmaceuticals and
Par Pharmaceuticals are expected to enter the market with their
generic versions by 2015.
Browse
all Press Releases:
http://www.transparencymarketresearch.com/press-releases.htm
Among
the infertility procedures, intrauterine insemination (IUI) is the
most preferred treatment procedure due to its low operational cost
and equal success rate compared to intracytoplasmic sperm injection
(ICSI) and in vitro fertilization (IVF), which follow IUI in terms of
preference. The simplicity of performing IUI is what attracts the
healthcare professionals to prefer this procedure over others. Zygote
intrafallopian transfer (ZIFT) and gamete intrafallopian transfer
(GIFT) are the least popular procedures performed worldwide,
accounting for about 0.1% of the total ART treatments. This is due to
the higher procedural costs and complexity in performing these
procedures.
Browse
all Article :
http://www.transparencymarketresearch.com/articles.htm
North
America dominated the global human reproductive technologies market
in 2012 and is expected to maintain its leading market position till
2019. However, the Asia-Pacific contraceptive technologies market is
estimated to grow at a faster pace (CAGR of 6.9% from 2013 to 2019)
mainly to the rising awareness and acceptance of reproductive
technologies in this region. Entry of large market players such as
Merck Serono, Ferring International Center S.A. and Merck & Co.,
Inc.will also drive the market in the Asia-Pacific region.
Some
of the key players in the global human reproductive technologies
market include Abbott Laboratories, Bayer AG, Merck & Co., Inc.,
Merck Serono, Teva Pharmaceutical Industries Ltd., Pfizer, Inc.,
Watson Pharmaceuticals and Reckitt Benckiser.
The
global human reproductive technologies market is categorized into the
following segments
Human
Reproductive Technologies Market, by Infertility Drugs
Gonal-f
(recombinant follitropin alfa)
Follistim
AQ (follitropin beta)
AndroGel
(testosterone)
Testim
(testosterone)
Viagra
(sildenafil citrate)
Cialis
(tadalafil)
Levitra/Staxyn
(vardenafil)
Human
Reproductive Technologies Market, by Infertility Procedures
In
Vitro Fertilization (IVF)
Intracytoplasmic
Sperm Injection (ICSI)
Zygote
Intrafallopian Transfer (ZIFT)
Gamete
Intrafallopian Transfer (GIFT)
Intrauterine
Insemination (IUI)
Human
Reproductive Technologies Market, by Contraceptive Technologies
Drugs
Oral
Contraceptive Pills
Contraceptive
Injectables
Topical
Contraceptives
Devices
Male Contraceptive Devices
(Male Condoms)
Female Contraceptive
Devices
Female Condoms
Diaphragms
Sponges
IUDs
Hormonal IUDs
Copper IUDs
Subdermal Contraceptive
Implants
Vaginal Rings
Human
Reproductive Technologies Market,by Geography
North
America
Europe
Asia-Pacific
Rest
of the World (RoW)
Browse
Pharmaceutical Market Research Reports @
http://www.transparencymarketresearch.com/pharmaceutical-market-reports-1.html
About
Us
Transparency
Market Research is a global market intelligence company, providing
global business information reports and services. Our exclusive blend
of quantitative forecasting and trends analysis provides
forward-looking insight for thousands of decision makers. We are
privileged with highly experienced team of Analysts, Researchers, and
Consultants, who use proprietary data sources and various tools and
techniques to gather, and analyze information.
Our
data repository is continuously updated and revised by a team of
research experts, so that it always reflects the latest trends and
information. With a broad research and analysis capability,
Transparency Market Research employs rigorous primary and secondary
research techniques in developing distinctive data sets and research
material for business reports.
Contact
Sheela
AK
90
Sate Street, Suite 700
Albany,
NY 12207
Tel:
+1-518-618-1030
USA
- Canada Toll Free: 866-552-3453
Email:
sales@transparencymarketresearch.com
Blog:
http://www.tmrblog.com/
No comments:
Post a Comment